|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | DOG1是一种敏感和特异性的胃肠道间质瘤的标记物显示文摘 | Espinosa I Lee C H Kim M K 黄文斌(摘译) | 2008 | 临床与实验病理学杂志2008，24，3： | 117 |
| 2 | 患者肠道微生物群失调与肠上皮屏障功能障碍显示文摘最近的证据表明,在动物模型中,肠道病理学和微生物组与高血压之间存在联系。然而,这种关联在人类中是否存在尚不清楚。因此,该研究的目的是检验高血压患者具有明显特异的肠道微生物组以及肠上皮屏障功能标记物和微生物组组成可以预测收缩压变化的假设。研究者通过鸟枪法宏基因组学分析粪便样本显示微生物分类和功能变化,结果显示高血压患者和对照受试者之间丁酸盐产生存在差异。 | Kim S Goel R Kumar A Qi Y Lobaton G Hosaka K Mohammed M Handberg EM Richards EM Pepine CJ Raizada MK 刘青 叶鹏 | 2018 | 中华高血压杂志2018，26，9： | 45 |
| 3 | CIPK9: a calcium sensor-interacting protein kinase required for low-potassium tolerance in Arabidopsis显示文摘钾是为在植物的很多个细胞的过程的主要宏营养素必需品之一。在土壤的低钾水平为庄稼生产代表一个限制因子。最近的研究识别了涉及钾获得的钾运输 ers,并且他们中的一些为在低钾条件下面的钾营养是批评的。然而,很少在涉及低钾发信号和回答的分子的部件上被理解。我们这里在 Arabidopsis 作为低钾反应的一个批评管理者报导 calcineurin 象 B 一样交往蛋白质的 proteinkinase (CIPK9 ) 的鉴定。CIPK9 基因对不能生活的压力条件应答,并且它的抄本由钾剥夺在根和射击是可诱导的。CIPK9 功能的混乱使变异的植物变为过分敏感到低钾媒介。进一步的分析显示那 K (+) 举起和内容没在变异的植物被影响,暗示在钾利用的规定的 CIPK9 或察觉到过程。 | Girdhar K Pandey Yong Hwa Cheongx Beom-Gi Kim John J Grant Legong Li Sheng Luan | 2007 | Cell Research2007，17，5： | 23 |
| 4 | Yes相关蛋白通过肿瘤坏死因子受体相关因子6控制内皮活化和血管炎症显示文摘继发于异常的内皮激活的微血管炎症和内皮功能障碍在败血症和器官衰竭的病理生理学中起关键作用。抑制内皮细胞过度活化的内在信号传导机制尚未完全明了。该研究旨在确定Yes相关蛋白(Yes-associated protein,YAP)(Hippo通路的主要转录共激活剂)在调节内皮活化和血管炎症的强度和程度中的中心作用。 | 刘青 叶鹏 Lv Y Kim K Sheng Y Cho J Qain Z Zhao YY Hu G Pan D Malik AB | 2018 | 中华高血压杂志2018，26，8： | 20 |
| 5 | 帕博利珠单抗(pembrolizumab)与化疗治疗微卫星不稳定性高/错配修复缺陷型转移性结直肠癌的比较:KEYNOTE-177的3期研究显示文摘背景:KEYNOTE-177 (NCT02563002)是一项3期随机、开放标签的临床研究,评估了帕博利珠单抗与标准化疗±贝伐珠单抗或西妥昔单抗作为微卫星不稳定性高/错配修复缺陷(MSI-H/d MMR)型转移性结直肠癌患者一线治疗的效果和安全性。本次公布了终期PFS分析的结果。方法:共有307名由当地医疗机构评判的MSI-H/d MMR且ECOG PS评分为0或1的转移性结直肠癌患者按1:1比例随机分组接受治疗,治疗方案为一线帕博利珠单抗(200 mg,Q3W,最长治疗时限为2年),或为研究者所选择的化疗方案,包括m FOLFOX6或FOLFIRI Q2W±贝伐珠单抗或西妥昔单抗(随机选择化疗方案)。治疗终止于出现PD、无法耐受的毒性、患者/研究者决定退出治疗或完成35个周期治疗(仅对于帕博利珠单抗而言)。确诊PD后,接受化疗组患者可转入帕博利珠单抗组并接受最长为35个周期的治疗。主要终点是PFS (RECIST v1.1,中心审查)和OS。主要的次要终点包括ORR (RECIST v1.1,中心审查)和安全性。该中期分析的数据截止日期是2020年2月19日。该研究仍将继续随访评估OS。结果:截止数据纳入时,153名患者被随机分至帕博利珠单抗组,154名患者被随机分至化疗组。帕博利珠单抗组的中位随访为28.4个月(0.2~48.3个月),化疗组为27.2个月(0.8~46.6个月)。帕博利珠单抗组PFS优于化疗组(中位时间16.5个月vs. 8.2个月;HR=0.60,95%CI:0.45~0.80,P=0.0002)。帕博利珠单抗组的12个月和24个月PFS率分别为55.3%和48.3%,化疗组则相应分别为37.3%和18.6%。帕博利珠单抗组与化疗组经确认的ORR分别为43.8%与33.1%;帕博利珠单抗组与化疗组中位持续反应时间分别为未达到(2.3+~41.4+个月)和10.6个月(2.8~37.5+个月)。帕博利珠单抗组3~5级与治疗相关的不良事件(AE)发生率为22%,化疗组为66%。化疗组中有1例患者因治疗相关的AE死亡。结论:与化疗相比,帕博利珠单抗作为MSI-H/d MMR型转移性结直肠癌的一线治疗可提供具有临床意义和统计学意义的PFS获益,同时观察到较少的与治疗相关的AE,应该成为这类患者的新的标准治疗方案。 | 陈功 ANDRé T SHIU K K KIM T W | 2020 | 结直肠肛门外科2020，26，6： | 15 |
| 6 | Hepatocellular carcinoma: Review of disease and tumor biomarkers显示文摘Hepatocellular carcinoma(HCC) is a common malignancy and now the second commonest global cause of cancer death. HCC tumorigenesis is relatively silent and patients experience late symptomatic presentation. As the option for curative treatments is limited to early stage cancers, diagnosis in non-symptomatic individuals is crucial. International guidelines advise regular surveillance of high-risk populations but the current tools lack sufficient sensitivity for early stage tumors on the background of a cirrhotic nodular liver. A number of novel biomarkers have now been suggested in the literature, which may reinforce the current surveillance methods. In addition, recent metabonomic and proteomic discoveries have established specific metabolite expressions in HCC, according to Warburg's phenomenon of altered energy metabolism. With clinical validation, a simple and non-invasive test from the serum or urine may be performed to diagnose HCC, particularly benefiting low resource regions where the burden of HCC is highest. | Jin Un Kim Mohamed I F Shariff Mary M E Crossey Maria Gomez-Romero Elaine Holmes I Jane Cox Haddy K S Fye Ramou Njie Simon D Taylor-Robinson | 2016 | World Journal of Hepatology2016，8，10： | 13 |
| 7 | 孕前血压及其到妊娠早期的变化:先兆子痫和妊娠期高血压的早期危险因素显示文摘先兆子痫和妊娠期高血压是常见的妊娠并发症,与母婴发病率显著相关。尽管对怀孕期间的危险因素进行了广泛的研究,但大多数患妊娠期高血压疾病的妇女并不被认为是高风险的,预防措施仍不清楚。研究者评估了妊娠前的血压及其到妊娠早期的变化,将其作为妊娠高血压疾病发展新的危险标志。 | 刘青(译) 刘莉(摘/审校) Nobles CJ Mendola P Mumford SL Silver RM Kim K Andriessen VC Connell M Sjaarda L Perkins NJ Schisterman EF | 2020 | 中华高血压杂志2020，28，12： | 12 |
| 8 | 热处理豆粕饲喂生长猪的氨基酸消化率显示文摘为测定热处理对豆粕(SBM)表观回肠消化率和标准回肠消化率(SID)的影响,本试验将常规去壳豆粕(48.5%蛋白)分成4组,一份未经额外热处理,一份在125℃下高压蒸汽处理15 min,一份在125℃下高压蒸汽处理30 min,另一份在125℃下烘箱烘干30 min。制定四种豆粕-玉米淀粉型日粮配方,且每个配方只能使用上述四种豆粕中的一种,作为每种日粮中唯一氨基酸来源。用无氮日粮配方来估算基础内源性氨基酸损失。分别在初始体重为(25.3±2.0)kg的10头阉公猪回肠末端安装一个T-型瘘管。采用5×5拉丁方设计法,将试验猪分成5个日粮处理组,5个重复处理周期。每个处理周期持续7 d,在第6天和第7天收集回肠食糜。试验结果表明,随着高压蒸汽处理时间(0~30 min)的延长,蛋白质和所有氨基酸的表观回肠消化率和标准回肠消化率呈线性降低(P<0.01)。糠氨酸含量和豆粕样品的颜色表明高压蒸汽处理导致豆粕产生美拉德反应。然而,125℃烘箱干燥30min并未改变豆粕中蛋白和氨基酸标准回肠消化率,也没有改变SBM的糠氨酸含量(P>0.10),且烘箱处理的样品颜色表明该样品并未受到热处理破坏。总之,热蒸汽处理时间从0 min增至30 min,高压蒸汽处理豆粕的氨基酸消化率呈线性降低,降低原因很可能是由于125℃高压蒸汽处理导致豆粕产生美拉德反应。 | González-Vega J C Kim B G Htoo J K Lemme A Stein H H | 2015 | 中国饲料2015，，24： | 8 |
| 9 | 室内TDR试验监测石灰矿渣加固粘性土的物理化学反应过程(英文)显示文摘石灰矿渣和水泥矿渣常用于加固道路基层的粘性土。目前现场一般采用未加固土的最大干密度和最优含水率来评价加固土的压实施工质量。但是粘性土掺加了石灰后,发生了复杂的物理化学反应,使得其压实特性与未加固土有很大的不同。采用时域反射计监测石灰加固土内的物理化学反应过程。试验时将不同石灰矿渣掺和量和含水率的Orchard粘土通过标准击实试验夯实于击实筒中,用TDR监测其中的物理化学反应,针式贯入仪监测强度的增长。试验发现,电导率和介电常数的变化反应了土中的离子交换和硬化反应的过程。初始电导率(1d之内)的减小揭示了石灰矿渣的掺和量的大小,而长期电导率的减小揭示了强度的增长。试验表明,时域反射计技术可用于评价石灰加固土的施工质量。 | 陈仁朋 DAITA R K DRNEVICH V P KIM D H | 2006 | 岩土工程学报2006，28，2： | 7 |
| 10 | 大气二氧化氮与每日总死亡率、心血管和呼吸系统疾病死亡率的短期关联:398个城市的多中心分析显示文摘目的:采用统一的分析方案,评估全球多个国家/地区的二氧化氮(NO_(2))与总死亡率、心血管和呼吸系统疾病死亡率之间的短期关联。研究设计:采用两阶段的时间序列分析方法、过度离散的广义线性模型和多水平meta分析。研究地点:22个低到高收入国家/地区的398个城市。主要结局指标:1973—2018年逐日总死亡人数(6280万人)、心血管疾病死亡人数(1970万人)和呼吸系统疾病死亡人数(550万人)。结果:平均而言,NO_(2)浓度在滞后1天(前1天)每增加10μg/m^(3),会导致总死亡率、心血管和呼吸系统疾病死亡率分别增加0.46%(95%可信区间0.36%~0.57%)、0.37%(0.22%~0.51%)、0.47%(0.21%~0.72%)。在对共污染物(PM_(10)、PM_(2.5)、臭氧、二氧化硫和一氧化碳)进行调整后,这些关联仍然很稳定。所有3种死因的暴露-反应曲线几乎是线性的,没有明显的阈值。在398个城市中,可归因于高过假定零水平的NO_(2)浓度造成的死亡比例为1.23%(95%可信区间0.96%~1.51%)。结论:这项多中心研究提供了关于NO_(2)短期暴露与总死亡率、心血管和呼吸系统死亡风险之间的独立和线性关联的关键证据,说明通过加强NO_(2)的控制和监管限制标准,可获得人群水平的健康收益。 | 孟夏 刘聪(校) 陈仁杰 郑湃(译) 阚海东(校) Francesco Sera Ana Vicedo-Cabrera Ai Milojevic Maria Guo Yuming Tong Shilu Micheline de Sousa Zanotti Stagliorio Coelh Paulo Hilario Nascimento Saldiva Eric Lavigne Patricia Matus Correa Nicolas Valdes Ortega Samuel Osorio Garcia Jan Kysely Ales Urban Hans Orru Marek Maasikmets Jouni J K Jaakkola Niilo Ryti Veronika Huber Alexandra Schneider Klea Katsouyanni Antonis Analitis Masahiro Hashizume Yasushi Honda Chris Fook Sheng Ng Baltazar Nunes João Paulo Teixeira Iulian Horia Holobaca Simona Fratianni Ho Kim Aurelio Tobias Carmeníniguez Bertil Forsberg ChristoferÅström Martina S Ragettli Yue-Liang Leon Guo Shih-Chun Pan Shanshan Li Michelle L Bell Antonella Zanobetti Joel Schwartz Tangchun Wu Antonio Gasparrini | 2021 | 英国医学杂志中文版2021，24，8： | 7 |
| 11 | Screening for gastric cancer in Asia: current evidence and practice显示文摘 | Wai K Leung Ming-shiang Wu Yasuo Kakugawa Jae J Kim Khay-guan Yeoh Khean Lee Goh Kai-chun Wu Deng-chyang Wu Jose Sollano Udom Kachintorn Takuji Gotoda Jaw-town Lin Wei-cheng You Enders KW Ng Joseph JY Sung | 2008 | Lancet Oncology2008，，3： | 7 |
| 12 | Laparoscopic complete mesocolic excision: West meets East显示文摘Complete mesocolic excision is a relatively new concept in western literature. It follows the same concept of total mesorectal excision and units' routinely performing complete mesocolic excisions have good pathological results as well as good improvements in overall survival, disease free survival and local recurrence. And yet unlike total mesorectal excision, uptake in the West has been relatively slow with many units sceptical of the true benefits gained by taking up a more technically challenging and potentially more morbid procedure when there is a paucity of literature to support these claims. This article reviews complete mesocolic excision for colon cancer, attempting to identify the risks and benefits of the technique and particularly looking at the reasons why its uptake has not been universal. It also discusses the similarities of a complete mesocolic excision to a colon resection with a D3 lymphadenectomy as well as the role of a laparoscopic approach to this technique. Considering a D3 lymphadenectomy has been the standard of care for stage Ⅱ and Ⅲ colon cancers in many of our Asian neighbours for over 20 years, combining this data with data on complete mesocolic excision may provide enough evidence to support or refute the need for complete mesocolic excisions. Maybe there might be lessons to be learnt from our colleagues in the east. | Carina F K Chow Seon Hahn Kim | 2014 | World Journal of Gastroenterology2014，20，39： | 6 |
| 13 | 4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8^(+) T cell proliferation显示文摘4-1BB(CD137)is a strong enhancer of the proliferation of CD8^(+)T cells.Since these cells require increased production of energy and biomass to support their proliferation,we hypothesized that 4-1BB signaling activated glucose and fatty acid metabolism.We found that treatment with agonistic anti-4-1BB mAb promoted the proliferation of CD8^(+)T cells in vitro,increasing their size and granularity.Studies with a glycolysis inhibitor and a fatty acid oxidation inhibitor revealed that CD8^(+)T cell proliferation required both glucose and fatty acid metabolism.Anti-4-1BB treatment increased glucose transporter 1 expression and activated the liver kinase B1(LKB1)-AMP-activated protein kinase(AMPK)-acetyl-CoA carboxylase(ACC)signaling pathway,which may be responsible for activating the metabolism of glucose and fatty acids.We also examined whether blocking glucose or fatty acid metabolism affected cell cycle progression and the anti-apoptotic effect of 4-1BB signaling.The increase of anti-apoptotic factors and cyclins in response to anti-4-1BB treatment was completely prevented by treating CD8^(+)T cells with the fatty acid oxidation inhibitor,etomoxir,but not with the glycolysis inhibitor,2-deoxy-D-glucose.We conclude that anti-4-1BB treatment activates glucose and fatty acid metabolism thus supporting the increased demand for energy and biomass,and that fatty acid metabolism plays a crucial role in enhancing the cell cycle progression of anti-CD3-activated CD8^(+)T cells in vitro and the anti-apoptotic effects of 4-1BB signaling on these cells. | Beom K Choi Do Y Lee Don G Lee Young H Kim Seon-Hee Kim Ho S Oh Chungyong Han Byoung S Kwon | 2017 | Cellular & Molecular Immunology2017，14，9： | 6 |
| 14 | Adipose stem cell-based regenerative medicine for reversal of diabetic hyperglycemia显示文摘Diabetes mellitus(diabetes) is a devastating disease that affects millions of people globally and causes a myriad of complications that lead to both patient morbidity and mortality. Currently available therapies, including insulin injection and beta cell replacement through either pancreas or pancreatic islet transplantation, are limited by the availability of organs. Stem cells provide an alternative treatment option for beta cell replacement through selective differentiation of stem cells into cells that recognize glucose and produce and secrete insulin. Embryonic stem cells, albeit pluripotent, face a number of challenges, including ethical and political concerns and potential teratoma formation. Adipose tissue represents an alternative source of multipotent mesenchymal stem cells, which can be obtained using a relatively simple, non-invasive, and inexpensive method. Similarly to other adult mesenchymal stem cells, adipose-derived stem cells(ADSCs) are capable of differentiating into insulin-producing cells. They are also capable of vasculogenesis and angiogenesis, which facilitate engraftment of donor pancreatic islets when co-transplanted. Additionally, anti-inflammatory and immunomodulatory effects of ADSCs can protect donorislets during the early phase of transplantation and subsequently improve engraftment of donor islets into the recipient organ. Although ADSC-therapy is still in its infancy, the potential benefits of ADSCs are far reaching. | Hyun Joon Paek Courtney Kim Stuart K Williams | 2014 | World Journal of Diabetes2014，5，3： | 5 |
| 15 | BK nephropathy in the native kidneys of patients with organ transplants: Clinical spectrum of BK infection显示文摘Nephropathy secondary to BK virus, a member of the Papoviridae family of viruses, has been recognized for some time as an important cause of allograft dysfunction in renal transplant recipients. In recent times, BK nephropathy(BKN) of the native kidneys has being increasingly recognized as a cause of chronic kidney disease in patients with solid organ transplants, bone marrow transplants and in patients with other clinical entities associated with immunosuppression. In such patients renal dysfunction is often attributed to other factors including nephrotoxicity of medications used to prevent rejection of the transplanted organs. Renal biopsy is required for the diagnosis of BKN. Quantitation of the BK viral load in blood and urine are surrogate diagnostic methods. The treatment of BKN is based on reduction of the immunosuppressive medications. Several compounds have shown antiviral activity, but have not consistently shown to have beneficial effects in BKN. In addition to BKN, BK viral infection can cause severe urinary bladder cystitis, ureteritis and urinary tract obstruction as well as manifestations in other organ systems including the central nervous system, the respiratory system, the gastrointestinal system and the hematopoietic system. BK viral infection has also been implicated in tumorigenesis. The spectrum of clinical manifestations from BK infection and infection from other members of the Papoviridae family is widening. Prevention and treatment of BK infection and infections from other Papovaviruses are subjects of intense research. | Darlene Vigil Nikifor K Konstantinov Marc Barry Antonia M Harford Karen S Servilla Young Ho Kim Yijuan Sun Kavitha Ganta Antonios H Tzamaloukas | 2016 | World Journal of Transplantation2016，6，3： | 4 |
| 16 | Current status of low dose multi-detector CT in the urinary tract显示文摘Over the past several years,advances in the technical domain of computed tomography(CT) have influenced the trend of imaging modalities used in the clinical evaluation of the urinary system.Renal collecting systems can be illustrated more precisely with the advent of multi-detector row CT through thinner slices,high speed acquisitions,and enhanced longitudinal spatial resolution resulting in improved reformatted coronal images.On the other hand,a significant increase in exposure to ionizing radiation,especially in the radiosensitive organs,such as the gonads,is a concern with the increased utilization of urinary tract CT.In this article,we discuss the strategies and techniques availablefor reducing radiation dose for a variety of urinary tractCT protocols with metabolic clinical examples.We also reviewed CT for hematuria evaluation and related scan parameter optimization such as,reducing the number of acquisition phases,CT angiography of renal donors and lowering tube potential,when possible. | Mi Kim Sung Sarabjeet Singh Mannudeep K Kalra | 2011 | World Journal of Radiology2011，3，11： | 4 |
| 17 | Power management unit chip design for automobile active-matrix organic light-emitting diode display module显示文摘A power management unit (PMU) chip supplying dual panel supply voltage, which has a low electro-magnetic interference (EMI) characteristic and is favorable for miniaturization, is designed. A two-phase charge pump circuit using external pumping capacitor increases its pumping current and works out the charge-loss problem by using bulk-potential biasing circuit. A low-power start-up circuit is also proposed to reduce the power consumption of the band-gap reference voltage generator. And the ring oscillator used in the ELVSS power circuit is designed with logic devices by supplying the logic power supply to reduce the layout area. The PMU chip is designed with MagnaChip’s 0.25 μm high-voltage process. The driving currents of ELVDD and ELVSS are more than 50 mA when a SPICE simulation is done. | KIM J H PARK J H KIM J H CAO T V LEE T Y BAN H J YANG K KIM H G HA P B KIM Y H | 2009 | Journal of Central South University2009，16，4： | 4 |
| 18 | Nat Genet:单基因突变导致过敏性皮炎的发生显示文摘最近,研究者们鉴定出了一类导致神经性皮炎发生的关键基因突变:CARDll。来自美国NIH过敏与传染病研究所的研究者们通过对四个没有血缘关系的患病家庭进行分析,发现了这一导致疾病产生的基因、 | Chi A Ma, Yuan Zhang, Michael A Weinreich, Jonathan J Lyons, Celeste G Nelson, Thomas DiMaggio, Kelly D Stone, Joshua D Milner Jeffrey R Stinson, Elisa Ruffo, Batsukh Dorjbal, Swadhinya Arjunaraja, Kelsey Voss, Andrew L Snow Jordan K Abbott, Pia J Hauk, Paul R Reynolds, Erwin W Gelfand Elisa Ruffo Salomé Glauzy, Natsuko Yamakawa, Eric Meffre Jennifer Stoddard, Julie Niemela, Sergio D Rosenzweig Yu Zhang, Helen F Matthews Joshua J McElwee Nina Jones Alejandro Palma, Matías Oleastro, Emma Prieto, Andrea R Bernasconi, Geronimo Dubra, Silvia Danielian, Jonathan Zaiat, Marcelo A Marti Brian Kim Megan A Cooper Neil Romberg | 2017 | 现代生物医学进展2017，17，27： | 3 |
| 19 | Intravenous immune globulin suppresses angiogenesis in mice and humans显示文摘Human intravenous immune globulin(IVIg),a purified IgG fraction composed of~60%IgG1 and obtained from the pooled plasma of thousands of donors,is clinically used for a wide range of diseases.The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG(IgG)Fc regions.Recently,we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI,a high-affinity receptor for IgG1.Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases,namely,neovascular age-related macular degeneration,corneal neovascularization,colorectal cancer,fibrosarcoma and peripheral arterial ischemic disease.Angioinhibition was mediated by the Fc region of IVIg,required FcγRI and had similar potency in transgenic mice expressing human FcγRs.Finally,IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities.These data place IVIg,an agent approved by the US Food and Drug Administration,as a novel angioinhibitory drug in doses that are currently administered in the clinical setting.In addition,they raise the possibility of an unintended effect of IVIg on blood vessels. | Reo Yasuma Valeria Cicatiello Takeshi Mizutani Laura Tudisco Younghee Kim Valeria Tarallo Sasha Bogdanovich Yoshio Hirano Nagaraj Kerur Shengjian Li Tetsuhiro Yasuma Benjamin J Fowler Charles B Wright Ivana Apicella Adelaide Greco Arturo Brunetti Balamurali K Ambati Sevim Barbasso Helmers Ingrid E Lundberg Ondrej Viklicky Jeanette HW Leusen J Sjef Verbeek Bradley D Gelfand Ana Bastos-Carvalho Sandro De Falco Jayakrishna Ambati | 2016 | Signal Transduction and Targeted Therapy2016，1，1： | 3 |
| 20 | Screening for gastric cancer in Asia: current evidence and practice显示文摘 | Wai K Leung Ming-shiang Wu Yasuo Kakugawa Jae J Kim Khay-guan Yeoh Khean Lee Goh Kai-chun Wu Deng-chyang Wu Jose Sollano Udom Kachintorn Takuji Gotoda Jaw-town Lin Wei-cheng You Enders KW Ng Joseph JY Sung | 2008 | Lancet Oncology2008，，3： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员